Dr. Grobmyer: Since 1995.

Of the breast cancer patients that you’ve treated, how often do you see that chemo and radiation had no impact?

Dr. Grobmyer: That’s hard to say in an individual patient. We make these recommendations based on large studies. So, we analyze the type of tumor that a patient has with certain gene assays for instance, and we can say that based on the gene expression profile the patient may only have a ten percent chance of recurrence. If a patient were to take chemotherapy based on the studies we have, they might benefit by one or two percent and many patients in that setting may say the benefit of chemotherapy is not worth the side effects. We’re able to specifically counsel patients about what their risks are and what the potential benefits are with certain treatments and that is where I think we’re continuing to move in this field.

You sound like you’re excited about where the treatment for breast cancer is going.

Dr. Grobmyer: It’s continually improving and we’re continually developing new drugs that I think we are offering patients more hope than ever for a chance for a cure.




Andrea Pacetti

Media Relations Manager

The Cleveland Clinic